Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.34 |
| ▸ | ERN1 | O75460 | 2/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.33 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4626756 | 0.77 | TXNRD1 (0.34) | PDE10ATXNRD1ERN1GSRL3MBTL1 | |
| SCHEMBL225571 | 0.75 | TXNRD1 (0.55) | TXNRD1GSR | |
| SCHEMBL14032801 | 0.69 | NNMT (0.50) | PDE10AERN1PDE2APDE5APDE4A | |
| SCHEMBL29935910 | 0.69 | NNMT (0.50) | PDE10AERN1PDE2APDE5APDE4A | |
| SCHEMBL29199342 | 0.69 | KDM4E (0.41) | ALDH1A1 | |
| SCHEMBL3571476 | 0.68 | ALDH1A1 (0.55) | PDE10AERN1ALDH1A1L3MBTL1GAA | |
| SCHEMBL153619 | 0.68 | PDE10A (0.35) | PDE10ATXNRD1GSRPDE2APDE5A | |
| SCHEMBL29779695 | 0.68 | PDE10A (0.35) | PDE10ATXNRD1GSRPDE2APDE5A | |
| SCHEMBL23046187 | 0.68 | ERN1 (0.42) | PDE10AERN1ALDH1A1L3MBTL1 | |
| SCHEMBL1534756 | 0.68 | ERN1 (0.52) | PDE10AERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642252-B2 | Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer. | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030166685-A1 | Acid derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| EP-1332131-A2 | ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002042273-A2 | ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166685-A1 | Acid derivatives useful as serine protease inhibitors | F9, F11, F12 | PDE10A 4092/4885TXNRD1 3967/4885ERN1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.